What is the proper name for cirrhosis due to Non-Alcoholic Steatohepatitis (NASH)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: April 7, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

From the Guidelines

The proper name for cirrhosis due to NASH is NASH cirrhosis or nonalcoholic steatohepatitis-related cirrhosis. This condition represents the advanced stage of nonalcoholic fatty liver disease (NAFLD) where inflammation and fibrosis have progressed to cirrhosis, as indicated by guidelines for liver transplantation in patients with non-alcoholic steatohepatitis 1. NASH cirrhosis develops when fat accumulation in the liver (steatosis) leads to inflammation, hepatocyte injury, and eventually extensive scarring that disrupts normal liver architecture and function. Some key points to consider in the diagnosis and management of NASH cirrhosis include:

  • Criteria for diagnosis of NASH-related cirrhosis should include an established clinical and histological diagnosis of NASH on liver biopsy, or a histological diagnosis of cryptogenic cirrhosis with a clinical phenotype compatible with underlying NASH, as defined by the presence of three or more components of the metabolic syndrome prior to liver transplant (LT) 1.
  • The progression from NAFLD to NASH and ultimately to cirrhosis typically occurs over many years, with some patients remaining asymptomatic until advanced liver disease develops.
  • Management focuses on treating the underlying metabolic conditions, weight loss, exercise, and monitoring for complications of cirrhosis such as portal hypertension, ascites, and hepatocellular carcinoma.
  • NASH may be the underlying cause of many cases of cryptogenic cirrhosis, particularly among older diabetic women, and there is evidence for an increased risk of HCC in patients with NASH 1.

From the Research

Definition of NASH Cirrhosis

  • NASH cirrhosis is a type of cirrhosis caused by nonalcoholic steatohepatitis (NASH) 2, 3, 4, 5, 6.
  • NASH is a condition characterized by inflammation and fat accumulation in the liver, which can lead to fibrosis and cirrhosis 3, 4.
  • The proper name for cirrhosis due to NASH is NASH cirrhosis or cryptogenic cirrhosis, as the exact cause of the liver damage is not always clear 5.

Characteristics of NASH Cirrhosis

  • NASH cirrhosis is often associated with metabolic syndrome, insulin resistance, and obesity 2, 4, 6.
  • Patients with NASH cirrhosis may have a higher risk of developing hepatocellular carcinoma and liver failure 3, 5.
  • The diagnosis of NASH cirrhosis is typically made through a combination of liver biopsy, imaging studies, and laboratory tests 2, 4, 6.

Treatment and Management

  • Treatment for NASH cirrhosis typically involves lifestyle modifications, such as weight loss and exercise, as well as medications to manage related conditions like diabetes and high blood pressure 2, 3, 4, 6.
  • Vitamin E and pioglitazone have been shown to improve liver histology and insulin sensitivity in patients with NASH 2, 3, 4, 6.
  • Liver transplantation may be considered in advanced cases of NASH cirrhosis 5.

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

State of the art: treatment of nonalcoholic steatohepatitis.

Current opinion in gastroenterology, 2014

Research

A pilot study of vitamin E versus vitamin E and pioglitazone for the treatment of nonalcoholic steatohepatitis.

Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, 2004

Research

Response to Pioglitazone in Patients With Nonalcoholic Steatohepatitis With vs Without Type 2 Diabetes.

Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, 2018

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.